AMENDMENT #14
Exhibit 10.1
CONFIDENTIAL TREATMENT REQUESTED
Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for confidential treatment.
AMENDMENT #14
TO LICENSE AGREEMENT ID LA0003Endocyte
Between Purdue Research Foundation and Endocyte Corporation
THIS AMENDMENT, made and entered into this 30'" day of January, 20 I 5 ("Amendment Effective Date") amends the Amended and Restated License Agreement executed on October 21st, 1998, and all subsequent Amendments (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte Corporation (hereinafter known as LICENSEE) with respect to the matters addressed in this Agreement.
NOW THEREFORE, the patties hereto do hereby agree as follows:
1. The technology, "Folate-Based Chimeric Antigen Receptor (CAR) T-Cells as Anti-Cancer Therapeutics" PRF Reference No. 66212 is added to Append ix A of the AGREEMENT.
2. The following Patents are added to Appendix A of the Agreement:
|
/ |
|||||
|
PRF Ref. No. |
Application # |
Status |
Type |
Filing Date |
Funding |
|
66212-01 |
61/740,384 |
Converted |
Provisional |
12/20/2012 |
Endocyte |
|
66212-02 |
PCT/US2013/076986 |
Published |
PCT |
12/20/2013 |
Endocyte |
All other terms and conditions of the original agreement remain unchanged and in effect.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.
Purdue Research FoundationEndocyte Corporation
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
By: __/s/ Xxxxx Razavi____By: __/s/ P. Xxx Ellis_____
Xxxxx RazaviP. Xxx Xxxxx
Acting Director, Corporate & New VenturesPresident/CEO
OTC
Date: _2-17-2015_________Date: _11 Feb 2015________
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
AMENDMENT #15
TO LICENSE AGREEMENT ID LA0003Endocyte
Between Purdue Research Foundation and Endocyte Corporation
THIS AMENDMENT, made and entered into this 20th day of May, 2015 ("Amendment Effective Date") amends the Amended and Restated License Agreement executed on October 21st , 1998, and all subsequent Amendments (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte Corporation (hereinafter known as LICENSEE) with respect to the matters addressed in this Agreement.
NOW THEREFORE, the parties hereto do hereby agree as follows:
l. The Eligible Disclosure, "Discovery of Synergy Between Folate-hapten Mediated
Immunotherapy and Receptor Tyrosine Kinase (rtk) Inhibitors for the Treatment of Cancers" PRF Reference No. 66939 is added to Appendix A of the AGREEMENT.
All other terms and conditions of the original agreement remain unchanged and in effect.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.
Purdue Research FoundationEndocyte Corporation
By: ___/s/ Xxxx X. Pittman__ By: __/s/ P. Xxx Ellis________
Xxxx X. XxxxxxxP. Xxx Xxxxx
Vice PresidentPresident/CEO
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Date: ___1 June 2015______Date: ___29 May 2015______
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
AMENDMENT #16
TO LICENSE AGREEMENT ID LA0003Endocyte
Between Purdue Research Foundation and Endocyte Corporation
THIS AMENDMENT, made and entered into this 4th day of June, 2015 ("Amendment Effective Date") amends the Amended and Restated License Agreement executed on October 21st, 1998, and all subsequent amendments (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte, Incorporated (hereinafter known as LICENSEE) with respect to the matters addressed in this agreement.
NOW THEREFORE, the parties hereto do hereby agree as follows:
1. The Eligible Disclosures, "Endosomal Escape" PRF Reference No. 65668 and PRF Ref. No.
67126 "A New Mechanism for Release of Endosomal Contents: Osmotic Disruption of Endosomes Via Nigericin-Mediated Potassium-Hydrogen Ion Exchange" have been combined and filed in US 62/159,659 and are added to Appendix A of the AGREEMENT.
All other terms and conditions of the original agreement remain unchanged and in effect.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.
Purdue Research FoundationEndocyte, Incorporated
By: ___/s/ Xxxx X. Xxxxxxx By: ____P. Xxx Ellis____
Xxxx X. PittmanP. Xxx Xxxxx
Vice PresidentPresident/CEO
Date: __July 28, 2015_____Date: ___June 17, 2015______
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
AMENDMENT #17
TO LICENSE AGREEMENT ID LA0003Endocyte
Between Purdue Research Foundation and Endocyte Corporation
THIS AMENDMENT, made and entered into this 24th day of June, 2016 ("Amendment Effective Date") amends the Amended and Restated License Agreement executed on October 21st, 1998, and all subsequent Amendments (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte, Inc. (hereinafter known as LICENSEE) with respect to the matters addressed in this Agreement.
NOW THEREFORE, the parties hereto do hereby agree as follows:
1. The following Eligible Disclosure is added to Appendix A of the AGREEMENT:
|
Title of Eligible Disclosure: |
[*] |
|
PRF Reference Number for Eligible Disclosure: |
[*] |
|
Contributors of the Eligible Disclosure: |
[*] |
2. The following Licensed Patents are added to Appendix A of the Agreement:
|
PRF Reference No. |
Title of Application |
Serial Number |
Inventors |
Filling Date |
Country |
Status |
|
[*] |
[*] |
[*] |
[*] |
[*] |
[*] |
[*] |
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
All other terms and conditions of the original agreement remain unchanged and in effect.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the Amendment Effective Date.
Purdue Research FoundationEndocyte, Inc.
By: ____/s/ Xxxxx X. Najem____By: __/s/ Xxxx Sherman_______________
Name: _____ Xxxxx X. Xxxxx __________ Name: ___Xxxx Sherman_______
Title: ______Corporate Counsel_________Title: ___ CEO____
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
AMENDMENT #18
TO LICENSE AGREEMENT ID LA0003Endocyte
Between Purdue Research Foundation and Endocyte Corporation
THIS AMENDMENT, made and entered into this 24th day of June, 20 16 ("Amendment Effective Date") amends the Amended and Restated License Agreement executed on October 21,1998, and all subsequent Amendments (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte, Inc. (hereinafter known as LICENSEE) with respect to the matters addressed in this Agreement.
NOW THEREFORE, the parties hereto do hereby agree as follows:
1. The following Eligible Disclosure is added to Appendix A of the AGREEMENT:
|
Title of Eligible Disclosure: |
Method of Treating Cancer by Targeting Tumor-Associated Macrophages |
|
PRF Reference Number for Eligible Disclosure: |
67565 |
|
Contributors of the Eligible Disclosure: |
Xxxxxx X. Low -Purdue University Xxxxxxxx Xx - Endocyte, Inc. Xxxxx Xxxxxxx - Endocyte, Inc. Xxxxxxxxxxx Xxxxxx -Endocyte, Inc. |
2. The following Licensed Patents are added to Appendix A of the Agreement:
|
PRF Reference No. |
Title of Application |
Serial Number |
Inventors |
Filling Date |
Country |
Status |
|
67565-03 |
Methods of Treating Cancer by Targeting Tumor- Associated Macrophages |
PCT/US2 015/06239 5 |
Xxxxxx X. Low Xxxxxxxx Xx Xxxxx Xxxxxxx Xxxxx Xxxxxx |
11-24-15 |
WO |
Filed |
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
All other terms and conditions of the original agreement remain unchanged and in effect.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the Amendment Effective Date.
|
Purdue Research Foundation |
Endocyte, Inc. |
|
|
By: /s/ Xxxxx X. Xxxxx |
|
By: /s/ Xxxx Xxxxxxx |
|
Name: Xxxxx X. Xxxxx |
|
Name: Xxxx Xxxxxxx |
|
Title: Corporate Counsel |
|
Title: CEO |
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
AMENDMENT #19
TO LICENSE AGREEMENT ID LA0003Endocyte
Between Purdue Research Foundation and Endocyte Corporation
THIS AMENDMENT, made and entered into this 21st day of February, 2017 (“Amendment Effective Date”) amends the Amended and Restated License Agreement executed on October 21st, 1998, and all subsequent Amendments (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte, Inc. (hereinafter known as LICENSEE) with respect to the matters addressed in this Agreement.
NOW THEREFORE, the parties hereto do hereby agree as follows:
|
1. |
The technology, “Folate-Based Chimeric Antigen Receptor (CAR) T-Cells as Anti-Cancer Therapeutics” PRF Reference No. 66212 (“Technology”) and all license and patent rights of the Technology granted under the AGREEMENT are terminated. |
|
2. |
The following Patents are removed from Appendix A of the AGREEMENT: |
|
PRF Ref # |
Title of Application |
Application Number |
Inventors |
Filing Date |
Country |
Status |
|
00000-00 |
Adoptive Cell Therapy Using Chimeric Antigen Receptor expressing T Cells for the Treatment of Cancers |
61/740,384 |
P. Low |
Dec. 20, 0000 |
Xxxxxx Xxxxxx (Provisional) |
Converted |
|
66212-02 |
CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS |
PCT/US2013/076986 |
P. Low, X. Xxx, and X. Xxx |
Dec. 20, 2013 |
PCT |
Nationalized |
|
3. |
All other terms and conditions of the AGREEMENT remain unchanged and in effect. |
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the Amendment Effective Date.
Purdue Research FoundationEndocyte, Inc.
By: _____/s/ Xxxxx X. Najem______By: ___/s/ Xxxx Sherman____
Name: ____ Xxxxx X. Xxxxx _____Name: ___ Xxxx Xxxxxxx _______
Title: _____Corporate Counsel ______Title: _____President and CEO__
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
